[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605317":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":44,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Routine follow-up group",null,"Patients in this cohor will be followed up every 24 weeks (or every 8-12 weeks for extremely high-risk population) routinely. Alpha fetoprotein, PIVKA-II, liver imaging examination, liver function, et al will be performed for these patients at each follow-up point.",{"label":13,"type":10,"description":14,"interventionNames":15},"AI system follow-up group","Patients in this cohor will be followed up every 24 weeks (or every 8-12 weeks for extremely high-risk population). Alpha fetoprotein, PIVKA-II, liver imaging examination, liver function, et al will be performed for these patients at each follow up point. An AI system will be used to manage follow-up patients.",[16],"Other: AI folow-up system",[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"AI folow-up system","In AI follow-up group, patients will be followed up by an AI system.",[13],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Bingliang Prof. Lin","CONTACT","+86-20-85252081","linbingl@mail.sysu.edu.cn",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Third Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510630","China",{"type":37,"coordinates":38},"Point",[39,40],113.25,23.11667,{"lat":40,"lon":39},[43],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lin Bingliang","Prof.","100605317",false,"NCT07160946","Risk Assessment for HBV-Related Liver Cancer","Research on Risk Assessment and Intervention of HBV-Related Liver Cancer Based on Multimodal Data Fusion","Inclusion Criteria: must meet (a) and any one of (b) to (g).\n\n* (a).Positive for Hepatitis B surface antigen; (b).Ultrasound\u002FCT\u002FMR indicates liver cirrhosis; (c). Type II diabetes; (d). Has family history of liver cirrhosis\u002F liver cancer; (e). Long term alcohol consumption history (\\>5 years), equivalent to alcohol consumption of ≥ 40g\u002Fd for males and ≥ 20g\u002Fd for females; (f). Liver histology Metavir fibrosis score F3 or above; (g). Fibroscan value (LSM) ≥ 8.0kPa.\n\nExclusion Criteria:\n\n* (a).Diagnosed with malignant tumors; (b). Post liver transplantation; (c). Infected with HIV; (d). Expected survival time\\\u003C1 year; (e). With marked organ dysfunctions(heart, brain, kidney, lung, endocrine system, blood, etc.) or psychiatric patients.","ALL","30 Years","75 Years",{"count":58,"type":59},6000,"ESTIMATED","5 Years","OBSERVATIONAL","Liver cancer is a severe disease worldwide. The incidence and mortality rates of liver cancer in China is the highest in the world. This project aims to perform a prospective, multi-center, large sample cohort study for HBV related high-risk individuals. Based on multimodal data fusion and AI technique, stratified management and follow-up system are conducted for HBV-related high-risk populations of liver cancer, in order to improve the early diagnosis rate of liver cancer.",[64],"HBV-related Liver Cirrhosis","2025-08-31",{"date":67,"type":68},"2025-09-08","ACTUAL",{"date":70,"type":68},"2025-05-10",{"date":72,"type":59},"2032-12-30",{"name":5,"class":6},1]